Pfizer brings back tortoise, hare in Chantix extended remix

Share this article:
Pfizer brings back tortoise, hare in Chantix extended remix
Pfizer brings back tortoise, hare in Chantix extended remix
Nine months after it pulled Chantix DTC amid concern about possible psychiatric side effects, Pfizer's tortoise and hare are back on the air with a new 90-second TV spot long on risk information.
 
Pfizer debuted DTC for the drug, launched in mid-2006, with print ads and 60-second spots in September 2007, but pulled DTC in January and strengthened the warning label amid reports of suicidal and other erratic behavior linked to the drug, however anecdotal.
 
The TV spot, dubbed “Take the First Step,” is by Interpublic Group's McCann HumanCare. It emphasizes the importance of patient-physician dialogue in smoking cessation and dwells on risk information, which takes up nearly half the ad and includes a warning that patients should stop taking Chantix if they experience agitation or suicidal impulses. The spot also stresses the value of counseling and support, including Pfizer's recently-retooled GetQuit Support Plan for Chantix.
 
“The Chantix approach is a pill with a program,” says the narrator, with a plummy English accent. “And because slip-ups happen, you can't have to much support, so include your doctor, friends and family, and consider GetQuit, a support plan for Chantix users.”

The firm also updated Chantix.com, executed by Publicis' Digitas Health, with new patient testimonials in its “Real People, Real Stories” section. Chantix was the top-searched prescription brand as of February, according to measurement firm comScore, and Pfizer's Chantix website for healthcare professionals was rated the number three product site for doctors last month by Manhattan Research – an indication of continuing interest in the drug among the medical community.
    
US sales of the drug for the first half of 2008 totaled $329 million, according to IMS Health data, with 3 million prescriptions dispensed. Last year sales were $682 million, with 7.3 million prescriptions dispensed. Pfizer spent almost $58 million in measured media advertising the drug to consumers through the end of 2007, according to TNS Media Intelligence data.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...